Læknablaðið - 15.05.2006, Page 24

FRÆÐIGREINAR / HÁÞRÝSTINGUR
adults in 61 prospective siudies. Lancet 2002; 360:1903-13.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC,
Green LA, Izzo JL Jr, et al. Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood pressure: the JNC 7 report.
Hypertension 2003; 42:1206-52.
6. 2003 European Society of Hypertension-European Society
of Cardiology guidelines for the management of arterial
hypertension. J Hypertens 2003; 21:1011-53.
7. Williams B, Poulter NR, Brown MJ, Davis M, Mclnnes GT,
Potter JF, et al. British Hypertension Society guidelines for
hypertension management 2004. BMJ 2004; 328: 634-40.
8. Hetlevik I, Holmen J, Kriiger O. Implementing clinical
guidelines in the treatment of hypertension in general practice.
Evaluation of patient outcome related to implementation of a
computer-based clinical decision support system. Scand J Prim
Health Care 1999; 17: 35-40.
9. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR.
Hypertension control: how well are we doing? Arch Intern
Med 2003; 163: 2705-11.
10. Primatesta P, Brookes M, Poulter NR. Improved hypertension
management and control: results from the health survey for
England 1998. Hypertension 2001; 38: 827-32.
11. Campbell NR, McAIister FA, Brant R, Levine M, Drouin D,
Feldman R, et al. Temporal trends in antihypertensive drug
prescriptions in Canada before and after introduction of the
Canadian Hypertension Education Program. J Hypertens
2003;21:1591-7.
12. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S,
Hansson L, et al. Outcomes in hypertensive patients at high
cardiovascular risk treated with regimens based on valsartan
or amlodipine: the VALUE randomised trial. Lancet 2004;
363: 2022-31.
13. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose
combination treatment with blood pressure lowering drugs:
analysis of 354 randomised trials. BMJ 2003; 326:1427-35.
14. Rodgers A. A cure for cardiovascular disease? Combination
treatment has enormous potential, especially in developing
countries. BMJ 2003; 326:1407-8.
15. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH,
Eberlein KA, et al. Blood pressure, stroke, and coronary
heart disease. Part 2, Short-term reductions in blood pressure:
overview of randomised drug trials in their epidemiological
context. Lancet 1990; 335: 827-38.
16. Blood Pressure Lowering Treatment Trialists4 Collaboration.
Effects of ACE inhibitors, calcium antagonists, and other
blood-pressure-lowering drugs: results of prospectively
designed overviews of randomised trials. Lancet 2000; 356:
1955-64.
17. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton
PK, He J. Global burden of hypertension: analysis of
worldwide data. Lancet 2005; 365: 217-23.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green
LA, Izzo JL Jr, et al. The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: the JNC 7 report. JAMA
2003; 289: 2560-71.
19. Campbell NC, Murchie P. Treating hypertension with
guidelines in general practice. BMJ 2004; 329: 523-4.
20. Poulter NR. NICE and BHS guidelines on hypertension differ
importantly. BMJ 2004; 329:1289.
21. Cederholm J, Nilsson PM, Anderberg CP, Fröberg L, Petersson
U. Blood pressure and other cardiovascular risk factors among
treated hypertensives in Swedish primary health care. Scand J
Prim Health Care 2002; 20: 224-9.
22. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman
M, Kadcr B, et al. Inadequate management of blood pressure
in a hypertensive population. N Engl J Med 1998; 339: 1957-
63.
23. Hajjar IM, Kotchen TA. Trends in prevalence, awareness,
treatment, and control of hypertension in the United States,
1988-2000. JAMA 2003; 290:199-206.
24. Pavlik VN, Hyman DJ. How well are we managing and
monitoring high blood pressure? Curr Opin Nephrol
Hypertension 2003; 12:299-304.
25. McKerracher A. Treating to hypertension targets. Heart 2004;
90 (Suppl IV): iv33-5.
26. Mosterd A, D‘Agostino RB, Silbershatz H, Sytkowski PA,
Kannel WB, Grobbee DE, et al. Trends in the prevalence of
hypertension, antihypertensive therapy, and left ventricular
hypertrophy from 1950 to 1989. N Engl J Med 1999; 340:1221-
7.
27. Oliveria SA, Lapuerta P, McCarthy BD, Litalien GJ,
Berlowitz DR, Asch SM. Physician-related barriers to the
effective management of uncontrolled hypertension. Arch
Intern Med 2002; 162:413-20.
28. Cohen JD. Superior physicians and the treatment of
hypertension. Arch Intern Med 2002; 162: 387-8.
29. Nilsson P, Andersson DK, Andersson PE, Schwan A, Ostlind
B, Malmborg R, et al. Cardiovascular risk factors in treated
hypertensives-a nation-wide, cross-sectional study in Sweden.
J Intern Med 1993; 233:239-45.
30. Bloom B. Continuation of initial antihypertensive medication
after 1 year of therapy. Clin Ther 1998; 20: 671-81.
31. Hyman DJ, Pavlik VN. Characteristics of patients with
uncontrolled hypertension in the United States. N Engl J Med
2001; 345: 479-86.
32. Ornstein SM, Nietert PJ, Dickerson LM. Hypertension
management and control in primary care: a study of 20
practices in 14 states. Pharmacotherapy 2004; 24: 500-7.
33. The ALLHAT Officers and Coordinators for the ALLHAT
Collaborative Research Group. Major outcomes in high-risk
hypertensive patients randomized to angiotensin-converting
enzyme inhibitor or calcium channel blockers. JAMA 2002;
288: 2981-97.
34. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG,
Caulfield M, et al. Prevention of cardiovascular events with
an antihypertensive regimen of amlodipine adding perindopril
as required versus atenolol adding bendroflumethiazide
as required, in the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a
multicentre randomised controlled trial. Lancet 2005; 365:
895-906.
380 Læknablaðið 2006/92